There is an ongoing Phase Ib/II clinical trial investigating the safety and efficacy of CDK4/6 inhibitor (SHR6390) combined with the anti-PD-1 antibody camrelizumab (SHR-1210) in patients with advanced CRC, HCC or NSCLC(NCT03601598). Here, CDK4 is linked to non-small cell lung carcinoma.